THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

Singapore’s UOB AM is currently one of just three offshore fund houses to have locally listed ETFs in Taiwan, along with ...

Continued efficacy and safety data generated by our study could support an FDA NDA submission directly, particularly as we plan to seek an accelerated approval of THIO in the U.S. “We have ...

“We expect that the results from this study will further illuminate THIO’s unmatched benefits for advanced stage NSCLC patients. “Our initiation of THIO-104 will mark an important milestone ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according ...

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...

Several lawyers in Singapore urged senior lawyer Chia Boon Teck to explain and apologise over his now-deleted LinkedIn post ...

CHICAGO, March 20, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company ...

With therapy, third-line patients generally survive about 6 months; without therapy, survival is only weeks,” said Vlad Vitoc, MAIA’s Chief Executive Officer. THIO (6-thio-dG or 6-thio-2 ...